On March 17, 2019, the first Bristol-Myers Squibb (BMS) Lung Cancer Immunotherapy Summit was successfully held in Chengdu. This conference brought together top experts and scholars in the field of lung cancer in China to discuss and exchange ideas on the latest research progress and hot topics in clinical practice in the field of lung cancer immunotherapy in China. During the meeting, [Tumor Information] interviewed Professor Wu Yilong of Guangdong Provincial People's Hospital and Professor Lu Shun of Shanghai Jiaotong University Affiliated Chest Hospital on site, and invited the two professors to elaborate on the standards of immunotherapy, the selection of lung cancer immunotherapy populations, and the current and future research directions of lung cancer immunotherapy. At the same time, the two professors also sent their wishes to the Lung Cancer Immunotherapy Summit Forum, looking forward to the successful holding of this meeting, which will have a positive impact on clinical practice, and to continue the activities in the future to contribute to the long-term promotion of the development of immunotherapy in China.